Dr. Constantine Mantz
/content/dam/us-photography/doctor-headshots/Profile-image_West-FL_RO_Constantine_Mantz_V3--gray.jpg

Constantine A. Mantz

Constantine A. Mantz
Constantine A.
Mantz
MD, FACRO
Radiation Oncologist

Languages spoken

English, French, Greek

Overview

Centers

Dr. Mantz joined GenesisCare in 2000 and serves as its Chief Policy Officer and Chief Physician Executive. He formerly served as Chief Medical Officer and Senior Vice President of Clinical Operations. As an area expert, he leads GenesisCare's focus on studying and treating prostate and breast cancer.

He is board-certified in Radiation Oncology by the American Board of Radiology. Dr. Mantz received his Bachelor of Science in Biology from the Loyola University of Chicago, IL, and his medical degree from the University of Chicago Pritzker School of Medicine, Chicago, IL.

Career Positions

  • GenesisCare - Chief Medical Officer and Radiation Oncologist, Fort Myers, FL
  • Chief Medical Officer for 21st Century Oncology

Education

Universities

  • Loyola University of Chicago, BS, Biology, Chicago, IL
  • University of Chicago Pritzker School of Medicine, Chicago, IL

Residency

  • University of Chicago Hospitals, Radiation Oncology, Chicago, IL

Internship

  • Hennepin County Medical Center, General Surgery, Minneapolis, MN

Expertise And Interests

Interests

  • Prostate, Breast, Lung, Colorectal, Head and Neck Malignancies

Professional associations

Publications

  • Numerous Radiation Therapy Research Projects Publishing Peer Reviewed Articles in Professional Publications
  • Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy
  • A Medicare Claims Analysis of Racial and Ethnic Disparities in the Access to Radiation Therapy Services. View publication
  • The ASTRO Perspective on "Impact of Patient Stage and Disease Characteristics on the Proposed Radiation Oncology Alternative Payment Model (RO-APM) at a Large Academic Cancer Center"
  • Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
  • Multi-institutional Analysis of Prostate-Specific Antigen Kinetics Following Stereotactic Body Radiotherapy (SBRT).

Presentations

Pragmatic test of amino acid mixture/enterade ® for Gastrointestinal Toxicity in Cancer therapy

Steven Finkelstein, Constantine Mantz, Laura Luque, Paul Okunieff, 2017, Multinational Association of Supportive Care in Cancer (MASCC)

In the media

In the media

Immunotherapy costs drive Medicare spending increase for end-of-life cancer care

April 14, 2023

View publication

Related videos

Thank you for submitting.

We will be in touch within 24 hours.

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

Our staff will provide answers to your questions within 24 hours. Otherwise, if you have a medical emergency please call 911.

*Indicates a required field